A Phase 2a, Randomized, Partially-blind, Placebocontrolled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and in Combination With a Nucleos(t)ide Analog in Subjects With Chronic Hepatitis B Virus Infection
Phase of Trial: Phase II
Latest Information Update: 30 Dec 2018
At a glance
- Drugs JNJ-56136379 (Primary) ; Entecavir; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Janssen Pharmaceutical KK; Janssen Sciences Ireland UC
- 31 Aug 2018 Biomarkers information updated
- 24 Aug 2018 Planned End Date changed from 31 Mar 2021 to 31 Aug 2021.
- 25 Apr 2018 Planned End Date changed from 26 Jun 2020 to 31 Mar 2021.